• 1
    Lok ASF. Chronic hepatitis B. N Engl J Med 2002; 346:16821683.
  • 2
    Hepatitis B. Fact sheet WHO/204. Revised October 2000.
  • 3
    Moradpour D, Wands JR. Molecular pathogenesis of hepatocellular carcinoma. In: ZakimD, BoyerTD, eds. Hepatology: A Textbook of Liver Disease. 4th Edition. Philadelphia: W.B. Saunders, 2002.
  • 4
    Kim WR, Brown RS, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36:227242.
  • 5
    Locarnini S, Birch C. Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating the HIV-infected patients. J Hepatol 1999; 30:536550.
  • 6
    Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag J, Schinazi RF. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33:751757.
  • 7
    Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, Rossau R. Line Probe Assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000; 38:702707.
  • 8
    Orito E, Mikozakami M, Ina Y, Moriyama EN, Kameshima N, Yamamoto M, Gojobori T. Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences. Proc Natl Acad Sci U S A 1989; 86:70597062.
  • 9
    Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, Wu PC, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:6168.
  • 10
    Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HWL, Goodman Z, Crowther L, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:12561263.
  • 11
    Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32:847851.
  • 12
    Leung NW, Lai CL, Guan R, Laiw YF. The effect of longer duration of harbouring lamivudine-resistant hepatitis B virus (YMDD mutants) on liver histology during 3 years lamivudine therapy in Chinese patients [Abstract]. Hepatology 2001; 34(Part 2):348A.
  • 13
    Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, et al., for the Adefovir Dipivoxil 437 Study Group. Adevovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808816.
  • 14
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang T, Kitis G, Rizzetto M, Marcellin P, et al for the Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348:800807.
  • 15
    Westland C, Yang H, Delaney W, Gibbs C, Miller M, Wulfsohn M, Fry J, et al. for the 437 and 438 Study teams. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003; 38:96103.
  • 16
    Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, et al. Resitance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292297.
  • 17
    Yang H, Westaland CE, Delaney WE, Heathcote EJ, Ho V, Fry J, Brosgard C, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36:464473.
  • 18
    Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: the final solution? Hepatology 2000; 32:430432.
  • 19
    Parekh S, Zoulim F, Ahn SH, Tsai A, Li J, Kawai S, Khan N, et al. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol 2003; 77:66016612.
  • 20
    Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991; 324:17051709.
  • 21
    Colonno RJ, Genovesi EV, Medina I, Lamb L, Durham SK, Huang M, Corey L, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Inf Dis 2001; 184:12361245.
  • 22
    College D, Civitico G, Locarnini S, Shaw T. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob Agents Chemother 2000; 44:551560.
  • 23
    Lau GKK, Tsiang M, Hou J, Yuen ST, Carmen WF, Zhang L, Gibbs CS, Lam S. Combination chemotherapy with lamivudine and famciclovir for chronic hepatitis B infected Chinese: a viral dynamics study. Hepatology 2000; 32:349399.